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Abstract
By applying an imputation strategy based on the 1000 Genomes project to two genome-wide association studies (GWAS),
we detected a susceptibility locus for venous thrombosis on chromosome 11p11.2 that was missed by previous GWAS
analyses that had been conducted on the same datasets. A comprehensive linkage disequilibrium and haplotype analysis of
the whole locus where twelve SNPs exhibited association p-values lower than 2.23 10
211 and the use of independent case-
control samples demonstrated that the culprit variant was a rare variant located ,1 Mb away from the original hits, not
tagged by current genome-wide genotyping arrays and even not well imputed in the original GWAS samples. This variant
was in fact the rs1799963, also known as the FII G20210A prothrombin mutation. This work may be of major interest not
only for its scientific impact but also for its methodological findings.
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Introduction
We had previously reported the results of two genome-wide
association studies (GWAS) for venous thrombosis (VT) conducted
in samples of French origin [1,2]. The first GWAS included 419
VT patients and 1,228 controls genotyped with the Illumina
Sentrix HumanHap 300 beadchip [1] while the second, composed
of 1,542 cases and 1,110 controls were genotyped with Illumina
Human 610Quad and 660W beadchips [2]. In both studies, cases
were unrelated VT patients, free of any chronic conditions and
without known major genetic risk factors including anti-thrombin,
protein C or protein S deficiency, homozygosity for FV Leiden
and FII G2021A mutations. Controls were healthy individuals
selected from two French national cohorts, the SUVIMAX [3]
and Three-City Study (3C) [4], respectively. The meta-analysis of
these two GWAS identified the well-established ABO, F5, F11 and
FGG genes and provided novel strong support in favor of HIVEP1,
PROCR and STAB2 loci as VT susceptibility genes [2]. This meta-
analysis was performed using imputed data derived from the
HapMap2 release 21 reference dataset containing 2,557,252
autosomal single nucleotide polymorphisms (SNPs). This genotype
resource, used in a very large number of meta-GWAS analyses, is
particularly efficient for testing the association with a phenotype of
non genotyped SNPs whose minor allele frequencies (MAF) are
greater than 5% [5]. However, it may not be adapted to infer the
association of SNPs with lower MAF. To overcome this limitation
and make possible the inference of rare SNPs with MAF as low as
1%, imputation analysis using data from the 1000 Genomes
project [6] has recently been proposed, and a few examples [7–10]
substantiated the interest of such approach.
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sTherefore, in this work, we re-analyzed these two GWAS on
VT based now on the 1000G 2010-08 release containing
11,572,501 autosomal SNPs, and validated novel results in two
additional case-control samples. A brief summary of the available
samples used in this work is shown in Figure 1.
Results
The imputation analysis was performed using MACH [11]
(v1.0.16a) (http://www.sph.umich.edu/csg/abecasis/mach/) and
Minimac (v4.4.3) (http://genome.sph.umich.edu/wki/Minimac)
software. 6,754,935 SNPs were imputed with good imputation
quality (r
2.0.3) [11] in both GWAS. The allele frequency
distribution of the imputed studied SNPs was shown in Figure
S1. Association of imputed SNPs with VT was tested using a
likelihood ratio test statistics implemented in the mach2dat
(v1.0.18) software (http://www.sph.umich.edu/csg/abecasis/
mach/) while adjusting for the first four principal components as
described in [2], separately in each GWAS. The results obtained
in the two GWAS were then combined using a fixed-effect meta-
analysis based methodology implemented in the METAL software
[12]. A Quantile-Quantile (QQ) plot representation of the results
was shown in Figure S2 and the resulting genomic control factor
was 0.993. 217 SNPs were found, at the genome-wide significant
at the 7.4610
29 level, consistently associated with VT across the
two GWAS samples (Table S1). These VT-associated SNPs
overlapped five loci on four chromosomes. Four of the loci
mapped the aforementioned ABO, F5, F11 and FGG genes while a
novel association involving the 11p11.2 locus (Table 1) was
identified. Twelve SNPs, from position 47,373,425 to 48,064,194
(according to hg19 reference) and overlapping the MYBPC3-SPI1-
CELF1-KBTBD4-NUP160-PTPRJ gene cluster demonstrated sig-
nificant associations with VT, ranging from P=6.97 10
213 to
P=2.23 10
211. All these SNPs had similar allele frequencies
(,3%) and similar genetic effects on VT risk (Odds Ratio (OR) ,
2.5) suggesting the existence of a strong linkage disequilibrium
(LD) block (pairwise r
2 or |D’|.0.8) explaining the association
signal observed at the 11p11.2 locus. This hypothesis was
supported by the results of a series of conditional logistic analyses
showing that after adjusting on any of these SNPs all other
observed associations at this locus vanished (P.0.10). Conversely,
genotyped SNPs at this locus exhibited low to moderate LD
(Figure 2) with median and 90
th percentile of the pairwise r
2
distribution being 0.10 and 0.52, respectively. We further
investigated the haplotype structure derived from the genotyped
SNPs using a previously described statistical methodology [13]
based on the Stochastic-EM algorithm [14]. For this, an Akaike
Information Criterion (AIC) based strategy was applied to our
largest GWAS [2] in order to identify the most informative and
parsimonious haplotypic model of 1 to 4 genotyped SNPs,
mapping 47,300,000 to 48,100,000, with respect to disease risk
prediction. The best identified combination included three SNPs,
rs2856650, rs3740689 and rs10769258, that generated six
haplotypes whose global distribution strongly differed between
cases and controls, consistently in both GWAS (Table 2). The
haplotypic association appeared to be mainly attributable to the
uncommon AGT haplotype that was more frequent in cases than
in controls. The Odds Ratio for VT associated with this AGT
haplotype was 2.37 [1.36–4.15] (P=2.39 10
23) and 2.99 [2.02–
4.44] (P=4.23 10
28) in the first and second GWAS, respectively)
(Table 2). When haplotype analyses were adjusted for the imputed
dose at any of the twelve SNPs, these ORs were reduced to 1.03
[0.41–2.58] (P=0.950) and 0.96 [0.55–1.66] (P=0.879) suggest-
ing that the AGT haplotype actually tagged the rare alleles of the
long range LD block.
To replicate the association observed at the 11p11.2 locus, we
genotyped two SNPs selected from Table 1, the MYBPC3
rs2856656 and the CELF1 rs60206633, in an independent sample
of 592 controls and 596 VT cases from the FARIVE study [1]. We
opted for the genotyping of two SNPs to further validate our
hypothesis that the detected imputed rare variants were in strong
LD. In FARIVE, the two SNPs were indeed in strong LD
(D’=+0.89, r
2=0.49) and showed evidence for association with
VT (Table 3). In particular, the rs2856656-G allele was associated
with an OR of 1.70 [1.15–2.51] (P=0.008; PBonferroni-corrected
=0.016). This pattern of association was very consistent with that
Figure 1. Case-control samples available in this work.
(1) These individuals were typed with the Illumina Sentrix HumanHap300 beadchip
containing 317,319 SNPs among which 291,872 satisfied the quality control (QC) criteria (Tre ´goue ¨t et al. (2009) Blood 113: 5298–5303).
(2) These
individuals were typed with the Illumina 610-Quad and Illumina 660W-Quad beadchips. Among the 551,141 SNPs common to both assays, 491,258
SNPs satisfied the QC criteria (Germain et al (2011) Plos One 6: e25581).
(a) 812 VT patients of the MARTHA study were part of the GWAS
(2) VT sample.
(b) The FV Leiden and FII G20210A mutations were genotyped in the GWAS patients as part of the study design where patients homozygous for these
mutations were excluded.
doi:10.1371/journal.pone.0038538.g001
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(Tables 1 & 2). Haplotype analysis of these two SNPs further
showed that the rs2856656-G allele was carried by two haplotypes
that were both more frequent in cases than in controls (Table S2).
One of these two haplotypes also carried the rare rs60206633-G
allele suggesting that the association signal observed at rs60206633
was due to its LD with rs2856656.
To further study the association of the 11p11.2 locus with VT,
we genotyped the MYBPC3 rs2856656 and the CELF1
rs60206633 in the MARTHA study [1] composed of 1150 VT
cases, among which 812 were part of the second GWAS, and a
new sample of 801 controls that were not part of any of the two
GWAS. By design, the control group of the MARTHA study had
been enriched in healthy individuals heterozygous for the FV
Leiden or FII G20210A mutations (,40% of all controls). The
association of rs2856656 with VT risk was not significant in
MARTHA. While the frequency of the rs2856656-G allele in
cases was comparable to that of other VT samples, in contrast it
was higher than expected in controls (Minor Allele Frequency
=0.069). Because of the enrichment of MARTHA controls in FV
and FII carriers, we further investigated the genotype distribution
of the rs2856656 according to the presence of FV and FII
mutations and observed that the frequency of the rs2856656-G
allele was strongly increased in FII carriers in all subgroups
(Table 4). Conditioning on FII G20210A mutation, the allele
frequency of the rs2856656 did not differ according to VT status
(Table 4). In FARIVE, a conditional logistic regression analysis
was conducted and revealed that, after adjusting for the FII
G20210A (rs1799963), the rs2856656-G allele was no longer
associated with VT risk (OR =1.26 [0.80–1.99], p=0.310). The
rs1799963 variant is located on chromosome 11 at a distance of
612 kb from rs2856656. The pairwise LD r
2 between these two
SNPs were 0.53 and 0.24 in MARTHA and FARIVE,
respectively, while the associated D’ were +0.86 and +0.68,
respectively.
Coming back to our imputation GWAS data, we observed that
the rs1799963 variant was imputed with poor quality (r
2=0.12
and r
2=0.27 in the first and second GWAS, respectively) and
thus did not pass the quality control. Nevertheless, it showed
suggestive association with VT, P=0.053 and P=0.110, in the
first and second GWAS, respectively, for a combined statistical
evidence of P=0.020. A conditional logistic regression analysis
was then conducted to estimate the effect of the imputed
rs2856656 after adjusting for the imputed rs1799963. As
indicated in Table 5, the imputed rs2856656-G allele was still
associated with increased risk for VT, P=7.22 10
24 and P=1.13
10
211, in the first and second GWAS, respectively. However,
because the rs1799963 variant was typed in the GWAS patients
as part of the inclusion/exclusion criteria (see Materials and
Methods), we re-ran the conditional analyses using the true
genotyped rs1799963 in cases rather than the imputed dose. The
association of rs2856656 with VT was now no longer significant,
P=0.643 and P=0.122, in the first and second GWAS
respectively (Table 5). To corroborate the poor quality of the
imputation at rs1799963 mentioned above, we calculated the
Spearman correlation between the imputed dose and the true
genotype at rs1799963 in all cases for whom both information
was available (Figure 1). This correlation was only r=0.36 and
r=0.48 in the 419 and 1,542 cases from the first and second
GWAS, respectively. As shown in Figure 3, the rs1799963
genotype was poorly imputed in heterozygotes individuals.
Finally, a further haplotype analysis revealed that the rare
Figure 2. Pairwise linkage disequilibrium r
2 between genotyped SNPs at the 11p11.2 locus over the 47,373,425–48,064,194 bp
region in the second GWAS study (Germain et al. Plos One 2011).
doi:10.1371/journal.pone.0038538.g002
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haplotype discussed above (Table S3). Of note, a LD analysis of
the whole chromosome 11 region from 46,600,000 to
48,000,000 bp containing 119 SNPs (Figure 4) showed that the
rs1799963 variant was not in strong pairwise LD with any other
common SNPs, the higher observed r
2 being 0.15 with AGBL2
rs7930612.
To summarize, in the two discovery GWAS based on imputed
data as well as in the two standard case-control samples where the
rs2856656 and the rs1799963 were directly genotyped, the
association of rs2856656 with VT vanished after adjusting for
rs1799963.
Finally, we re-analyzed the two imputed GWAS datasets by
conditioning on the previously identified VT-associated SNPs at
ABO, HIVEP1, FV, F11, FGG, PROCR and STAB2 loci [2]. Except
the 11p11.2 locus that remained genome-wide significant, no other
locus demonstrated statistical association at P,1.0 10
26.
Table 1. Genome-wide significant association (p,1.610















MYBPC3 47373425 rs2856656 A/G 0.032 1.598 0.257 2.76 10
–12 .8237 0.016 1.242 0.347 4.82 10
24 .7624 1.03 10
212
SPI1 47389771 chr11:47389771 C/G 0.035 1.628 0.247 1.09 10
213 .8371 0.018 1.044 0.328 1.92 10
23 .7719 6.97 10
213
CELF1 47565138 chr11:47565138 T/C 0.031 1.748 0.27 5.13 10
213 .7389 0.015 1.075 0.367 4.21 10
23 .7162 3.64 10
212
47574081 rs60206633 C/G 0.031 1.73 0.267 5.47 10
213 .7444 0.016 1.061 0.364 4.41 10
23 .7211 3.69 10
212
KBTBD4 47598481 chr11:47598481 G/A 0.031 1.735 0.268 4.30 10
213 .7584 0.016 0.964 0.368 1.06 10
22 .7286 1.24 10
211
FNBP4 47764906 rs78261087 G/A 0.034 1.539 0.24 1.08 10
212 .8358 0.017 0.864 0.339 1.29 10
22 .7912 1.99 10
211
47783614 chr11:47783614 T/C 0.034 1.528 0.239 1.11 10
212 .8417 0.017 0.858 0.336 1.30 10
22 .7957 2.23 10
211
NUP160 47818310 rs58883118 C/T 0.035 1.526 0.237 8.22 10
213 .8520 0.017 0.86 0.332 1.18 10
22 .8166 1.52 10
211
47920993 chr11:47920993 G/T 0.034 1.411 0.232 2.06 10
211 .8796 0.016 1.048 0.333 2.19 10
23 .8525 1.13 10
211
47947894 chr11:47947894 C/T 0.022 2.153 0.351 4.27 10
212 .6464 0.011 1.45 0.465 2.42 10
23 .6459 1.25 10
211
PTPRJ 48052066 rs117784795 C/T 0.039 1.315 0.207 2.67 10
212 .9417 0.020 0.775 0.29 9.28 10
23 .8986 1.78 10
211
48064194 chr11:48064194 G/A 0.038 1.311 0.207 2.94 10
212 .9746 0.020 0.856 0.296 4.99 10
23 .9286 7.52 10
212
(a) SNPs for which no rsID has yet been allocated are named according to their position on chromosome 11.
(b) Minor Allele Frequency.
(c) P-value of the association between imputed SNPs and VT risk, after adjusting for principal components.
(d) Imputation quality criterion (r
2).
(e) Combined meta-analysis p-value obtained using the Mantel-Haenszel inverse-variance weighting method.
doi:10.1371/journal.pone.0038538.t001
Table 2. Association of haplotypes derived from rs2856650, rs3740689 and rs10769258 with VT risk in two GWAS.
Polymorphisms GWAS from [2] GWAS from [1]










G G T 0.356 0.329 reference 0.332 0.335 reference
G A T 0.282 0.283 1.07 [0.93–1.24]
p=0.316
0.298 0.301 0.99 [0.82–1.22]
p=0.983
G A C 0.049 0.041 0.91 [0.68–1.21]
p=0.521
0.046 0.037 0.79 [0.51–1.23]
p=0.292
A G T 0.021 0.058 2.99 [2.02–4.44]
p=4.23 10
28
0.017 0.040 2.37 [1.36–4.15]
p=2.39 10
23
A A C 0.260 0.260 1.07 [0.93–1.24]
p=0.341
0.275 0.261 0.94 [0.76–1.15]
p=0.545
A A T 0.019 0.017 0.99 [0.59–1.66]
p=0.964
0.019 0.013 0.65 [0.27–1.57]
p=0.335
Global test of haplotypic
association
x
2=40.38 with 5 df p=1.25 10
27 x
2=11.24 with 5 df p=0.046
The meta-analysis of the AGT haplotype-associated ORs obtained in the two GWAS samples lead to an overall OR of 2.78 [2.01–3.81] (p=4.72 10
210). In a combined
analysis of the individual-level genotype data of the two GWAS, the AGT haplotype frequency was estimated to 0.054 and 0.019 in cases and controls, respectively. This
led to a combined OR of 3.03 [2.23–4.10] (p=8.96 10
213) compared to the most frequent GGT haplotype (with estimated frequency 0.330 and 0.343 in cases and
controls, respectively).
doi:10.1371/journal.pone.0038538.t002
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By conducting an updated and comprehensive in-depth analysis
of two GWAS, we were able to ‘‘re-discover’’ a strong risk locus for
VT known for more than one decade [15], the F2 gene, but missed
by all large scale association studies conducted so far on the disease
[1,2,16]. Several conclusions can be drawn from this work. First, it
adds to the rather limited illustrative literature about the interest of
imputation-based GWAS analyses using the 1000 Genomes project
that can help identify rare variants in new disease-associated loci not
detected by the first waves of GWAS; Second, the functional variant
could be quite far away from the detected hits. In our example, the
originalassociationsignalmappedtoanintervalfrom47,373,425 bp
(MYBPC3)t o4 8 , 0 6 4 , 1 9 4b p( PTPRJ) on chromosome 11, and this is
up to 1.3 Mb away from the functional G20210A mutation. Would
PTPRJ have been a plausible biological candidate for VT, our quest
for the culprit variant could have led us to a dead end; Third, a
functional variant could be missed if its imputation quality is low
which would likely be the case for a non genotyped rare variant
showing low to modest pairwise LD with other SNPs in its
neighborhood. As shown in Figure 5, imputation quality was
satisfactory for SNPs with inferred MAF .0.01. About 75% of the
SNPs with MAF ,0.01 demonstrated poor imputation quality in
our study while ,82% of the SNPs with MAF .0.01 were correctly
(r
2.0.3) imputed. Rare variants, like FII G20210A, which are not
present on genotyping arrays can nevertheless be tagged by
haplotypes generated from common SNPs not necessarily in strong
Table 3. Association of MYPBC3 rs2856656 and CELF1 rs60206633 with VT in the FARIVE study.
rs2856656 Controls Cases rs60206633 Controls Cases
AA 510 (93%) 487 (88%) CC 529 (94%) 527 (92%)
AG 38 (7%) 66 (12%) CG 30 (6%) 46 (8%)
GG 2 (,1%) 2 (,1%) GG 1 (,1%) 2 (,1%)
MAF
(a) 0.038 0.063 0.029 0.044
Cochran-Armitage Trend test p=0.008 p=0.062
(a)Minor Allele Frequencies.
doi:10.1371/journal.pone.0038538.t003
Table 4. Genotype distribution of the MYPBC3 rs2856656 according to VT status and carrier-ship of F5/F2 mutations in the
MARTHA and FARIVE studies.
MARTHA Controls MARTHA VT Cases
rs2856656 Non carriers FV Leiden carriers FII G20210A carriers Non carriers FV Leiden carrier FII G20210A carriers
AA 458 (97%) 174 (99%) 49 (35%) 563 (99%) 377 (98%) 53 (33%)
AG 13 (3%) 2 (1%) 91 (65%) 6 (1%) 8 (2%) 106 (67%)
GG 1 (,1%) 0 (-) 1 (,1%) 1 (,1%) 0 (-) 0 (-)
MAF
(a) 0.016 0.006 0.333 0.007 0.010 0.333
FARIVE Controls FARIVE VT Cases
rs2856656 Non carriers FV Leiden carriers FII G20210A carriers Non carriers FV Leiden carriers FII G20210A carriers
AA 478 (94%) 24 (100%) 5 (33%) 427 (93%) 48 (91%) 8 (24%)
AG 28 (6%) 0 (-) 9 (60%) 32 (7%) 5 (9%) 24 (73%)
GG 1 (,1%) 0 (-) 1 (7%) 0 (-) 0 1 (3%)
MAF 0.030 0.00 0.367 0.035 0.047 0.394
(a)Minor Allele Frequencies.
doi:10.1371/journal.pone.0038538.t004
Figure 3. Box-Plot representation of the imputed dose at
rs1799963 (FII G20210A) according to measured genotypes in
a sample of 1,961 VT cases. The imputed dose in the 419 VT cases of
the first GWAS is shown in blue while results obtained in the 1,542 VT
part of the second GWAS are shown in red.
doi:10.1371/journal.pone.0038538.g003
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atthe LPA locusassociated with coronary arterydisease[13].Froma
population genetics perspective, it would be interesting to investigate
whether evolutionary selection forces could be exerted on the F2
locus as suspected for the F5 gene [17,18] and could explain why a
functional ‘‘deleterious’’ allele was maintained on long-range
haplotype.
To conclude, we have shown how a comprehensive analysis of
1000G imputed genotype data was able to discover a disease locus
missed by previous GWASes. Our work also demonstrates the
need for exercising careful analysis of detected imputed rare
associations to avoid false inference on the functional variant, and
for this, LD and haplotype analyses of the associated loci may be of
great value. This may have both scientific and methodological
utility for geneticists involved in similar studies.
Materials and Methods
Ethics Statement
Each individual study was approved by its institutional ethics
committee and informed written consent was obtained in
accordance with the Declaration of Helsinki. All subjects were of
European origin. All subjects were of European origin.
Ethics approval were obtained :
– for MARTHA, from the ‘‘Departement sante ´ de la direction
ge ´ne ´rale de la recherche et de l’innovation du ministe `re’’
(Projects DC: 2008-880 & 09.576).
– for FARIVE, from the ‘‘Comite ´ consultatif de protection des
personnes dans la recherche biomedicale’’ (Project nu 2002-
034).
– for the 3C study, from the institutional ethics committees of the
Kremlin-Bicetre Hospital.
Studied populations
The description of the studied populations has already been
extensively described in [1] for the first GWAS MARTHA and
FARIVE studies, and in [2] for the second GWAS.
Briefly, all studied patients were unrelated Caucasians subjects
with a document first event of VT and lacking strong known
genetic risk factors, including AT, PC, or PS deficiencies, and
Figure 4. Pairwise linkage disequilibrium r
2 between genotyped SNPs mapping from F2 to PTPRJ genes at the 11p11.2 locus in a
sample of 1,542 VT cases.
doi:10.1371/journal.pone.0038538.g004





























1000 Genomes GWAS on Venous Thrombosis
PLoS ONE | www.plosone.org 6 June 2012 | Volume 7 | Issue 6 | e38538homozygosity for FV Leiden or FII 20210A mutation. Cases
(n=453) from the first GWAS were patients with early age of
onset of VT (,50 years) recruited in 4 different French centers
(Grenoble, Marseille, Montpellier, and Paris), and were compared
to 1,327 national French controls [3] with no chronic conditions,
and no regular medicines. Patients of the second GWAS
(n=1,597) were recruited from the Thrombophilia center of La
Timone hospital (Marseille, France) with no restriction one age of
onset, and were compared to another independent sample of
1,140 French controls free of any chronic disease and selected
from the 3C study [4]. The MARTHA study was composed of
1,150 VT patients also recruited from the Thrombophilia center
of La Timone hospital, among which 812 were part of the second
GWAS, and of a control sample of 801 healthy individuals. 475 of
these controls were recruited from the Marseille area and 326 were
healthy heterozygous carriers of the FV Leiden or FII G20210A
mutations selected from the national health examination centers of
the French Social Security in collaboration with the Hemostasis
and Thrombosis Study Group. The FARIVE study is a
multicenter case-control study composed of 607 patients with a
documented first episode of VT and 607 controls matched for age
and sex.
Genotyping and Quality control
First Genome Wide Association Study [1]. Individuals
participating in this GWAS were genotyped for 317,139 SNPs
using the Illumina Sentrix HumanHap300 Beadchip. The
application of several quality control criteria previously described
[1] lead the final analysis of 291,872 genotyped SNPs in a sample
of 419 cases and 1,228 controls.
Second Genome Wide Association Study [2]. As exten-
sively described in [2], 1011 VT patients were typed with the
Illumina Human 610-Quad Beadchip and 586 VT patients were
typed with the Illumina Human 660W-Quad Beadchip. Healthy
individuals from the 3C study were typed with the Illumina
Human 610-Quad Beadchip. The application of quality control
filters lead to the final analysis of 481,0002 autosomal SNPs in a
sample of 1,542 VT patients and 1,110 healthy individuals.
Replication studies. In FARIVE and MARTHA, the
MYBPC3 rs2856656 and the CELF1 rs60206633 were genotyped
by allele-specific PCR.
Statistical Analysis
Imputation. In both GWAS datasets, imputation of
11,572,501 autosomal SNPs was conducted using the MACH
[11] according the 1000G 2010-08 release reference dataset. The
association of each imputed SNP with VT was tested by use of a
logistic regression analysis in which allele dosage (from 0 to 2
copies of the minor allele) of imputed SNPs was used. Analyses
were adjusted for the first four principal components and were
performed using the mach2dat (v 1.0.18) software (http://www.
sph.umich.edu/csg/abecasis/MACH/download/).
Combined GWAS analysis. All SNPs with acceptable
imputation quality (r
2.0.3) in both imputed GWAS datasets were
entered into a meta-analysis, leading to 6,754,935 SNPs left for
statistical association analysis. For the meta-analysis, a fixed-effect
model relying on the inverse-variance weighting was used as
implemented in the METAL software [12]. Homogeneity of
associations across the two GWAS studies was tested using the
Mantel-Haenszel method [19]. A statistical threshold of 7.4 10
29,
which controls for the Bonferroni corrected type I error rate of
0.05 according to the number of tested SNPs, was used to declare
genome-wide significance.
Haplotype analysis. A systematic analysis of all possible
combinations of 1 to 4 typed SNPs within the chromosome 11
47,300,000–48,100,000 interval was performed to select the most
informative and parsimonious haplotype configuration in terms of
predicting disease status using a previously described strategy
based on the Akaike’s Information Criterion (AIC) [13]. This
strategy calculates an AIC value for each investigated haplotype
model and then subtracts from each model the minimum AIC
value obtained over all models explored, giving a rescaled AIC
value for each haplotype model. The models with a rescaled AIC
#2 are considered equivalent to the most informative model.
Among these equivalent models, the most parsimonious model
with the fewest polymorphisms is considered the best model. The
THESIAS program implementing the stochastic-EM algorithm
[14] for haplotype inference was used to estimate haplotype
frequencies and haplotype effects on VT risk derived from specific
sets of SNPs.
Replication. In the FARIVE and MARTHA studies, asso-
ciation of tested SNPs with VT risk was assessed by use of the
Cochran-Armitage trend test [20] and logistic regression models.
Figure 5. Box-Plot representation of the imputation quality (r
2) according to the minor allele frequency of the SNPs inferred from
1000G 2010-08 release. Box-plot derived from the imputation analysis of the largest GWAS
(2).
doi:10.1371/journal.pone.0038538.g005
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Figure S1 Distribution of the inferred minor allele
frequencies in two imputed GWAS datasets. Only SNPs
with imputation quality control r
2 . 0.30 are represented.
(TIF)
Figure S2 Quantile-Quantile plots summarizing the
results of a meta-analysis of two GWAS for VT. QQ plot
derived from SNPs imputed according to 1000G 2010-08 release
is shown in blue with its 95% confidence interval in shaded area.
The corresponding genomic control coefficient was 0.993. QQ
plot derived from HapMap2 release 21 imputed data is shown in
black with a genomic control of 1.023.
(TIF)
Table S1 Genome-wide significant (p,7.4610–9) SNPs
associated with VT risk in a meta-analysis of two
imputed GWAS datasets. Results are shown in a separate
EXCEL file (Table S1). Beta: log Odds Ratio for VT risk
associated with the A2 allele SE: Standard error of the beta
coefficient r
2: imputation quality control coefficient.
(XLSX)
Table S2 Haplotype frequencies distribution derived
from the MYBPC3 rs2856656 and CELF1 rs60206633
according to VT status in the FARIVE study.
(DOCX)
Table S3 Main haplotype frequencies distribution de-
rived from the rs2856650, rs3740689, rs10769258, and
rs1799963 in two samples of genotyped VT patients.
(DOCX)
Author Contributions
Conceived and designed the experiments: LL JCL AMD MB MCA JE ML
PA PEM DAT. Performed the experiments: NS DZ. Analyzed the data:
MG TOM JCL DAT. Contributed reagents/materials/analysis tools: JCL
ML NS DZ. Wrote the paper: FC LT PEM DAT.
References
1. Tregouet DA, Heath S, Saut N, Biron-Andreani C, Schved JF, et al. (2009)
Common susceptibility alleles are unlikely to contribute as strongly as the FV
and ABO loci to VTE risk: results from a GWAS approach. Blood 113:
5298–5303.
2. Germain M, Saut N, Greliche N, Dina C, Lambert J, et al. (2011) Genetics of
Venous Thrombosis: Insights from a New Genome Wide Association Study.
Plos One 6: e25581.
3. Hercberg S, Galan P, Preziosi P, Bertrais S, Mennen L, et al. (2004) The
SU.VI.MAX Study: a randomized, placebo-controlled trial of the health effects
of antioxidant vitamins and minerals. Arch Intern Med 164: 2335–2342.
4. Group CS (2003) Vascular factors and risk of dementia: design of the Three-City
Study and baseline characteristics of the study population. Neuroepidemiology
22: 316–325.
5. Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorff LA, et al. (2009)
Finding the missing heritability of complex diseases. Nature 461: 747–753.
6. Consortium TGP (2010) A map of human genome variation from population-
scale sequencing. Nature 467: 1061–1073.
7. Liu JZ, Tozzi F, Waterworth DM, Pillai SG, Muglia P, et al. (2011) Meta-
analysis and imputation refines the association of 15q25 with smoking quantity.
Nat Genet 42: 436–440.
8. Han SS, Yeager M, Moore LE, Wei MH, Pfeiffer R, et al. (2011) The
chromosome 2p21 region harbors a complex genetic architecture for association
with risk for renal cell carcinoma. Hum Mol Genet.
9. Day-Williams AG, Southam L, Panoutsopoulou K, Rayner NW, Esko T, et al.
(2011) A variant in MCF2L is associated with osteoarthritis. Am J Hum Genet
89: 446–450.
10. Farrell JJ, Sherva RM, Chen ZY, Luo HY, Chu BF, et al. (2011) A 3-bp deletion
in the HBS1L-MYB intergenic region on chromosome 6q23 is associated with
HbF expression. Blood 117: 4935–4945.
11. Li Y, Willer CJ, Ding J, Scheet P, Abecasis GR (2010) MaCH: using sequence
and genotype data to estimate haplotypes and unobserved genotypes. Genet
Epidemiol 34: 816–834.
12. Willer CJ, Li Y, Abecasis GR (2010) METAL: fast and efficient meta-analysis of
genomewide association scans. Bioinformatics 26: 2190–2191.
13. Tregouet DA, Konig IR, Erdmann J, Munteanu A, Braund PS, et al. (2009)
Genome-wide haplotype association study identifies the SLC22A3-LPAL2-LPA
gene cluster as a risk locus for coronary artery disease. Nat Genet 41: 283–285.
14. Tregouet DA, Escolano S, Tiret L, Mallet A, Golmard JL (2004) A new
algorithm for haplotype-based association analysis: the Stochastic-EM algo-
rithm. Ann Hum Genet 68: 165–177.
15. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM (1996) A common genetic
variation in the 39-untranslated region of the prothrombin gene is associated
with elevated plasma prothrombin levels and an increase in venous thrombosis.
Blood 88: 3698–3703.
16. Bezemer ID, Bare LA, Doggen CJ, Arellano AR, Tong C, et al. (2008) Gene
variants associated with deep vein thrombosis. Jama 299: 1306–1314.
17. Lindqvist PG, Svensson PJ, Dahlback B, Marsal K (1998) Factor V Q506
mutation (activated protein C resistance) associated with reduced intrapartum
blood loss – a possible evolutionary selection mechanism. Thromb Haemost 79:
69–73.
18. Lindqvist PG, Zoller B, Dahlback B (2001) Improved hemoglobin status and
reduced menstrual blood loss among female carriers of factor V Leiden – an
evolutionary advantage? Thromb Haemost 86: 1122–1123.
19. Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from
retrospective studies of disease. J Natl Cancer Inst 22: 719–748.
20. Sasieni PD (1997) From genotypes to genes: doubling the sample size. Biometrics
53: 1253–1261.
1000 Genomes GWAS on Venous Thrombosis
PLoS ONE | www.plosone.org 8 June 2012 | Volume 7 | Issue 6 | e38538